Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leronlimab in Moderately Ill COVID-19 Pneumonia
NCT04901676Phase 3Suspended
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of leronlimab in COVID-19 pneumonia, sponsored by Hospital Israelita Albert Einstein. Primary endpoint: Cumulative incidence of death or respiratory failure at 28 days. Started Sep 2021; status: suspended.
02
Drugs
leronlimab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04901676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901676.